JPWO2020174283A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020174283A5 JPWO2020174283A5 JP2021549617A JP2021549617A JPWO2020174283A5 JP WO2020174283 A5 JPWO2020174283 A5 JP WO2020174283A5 JP 2021549617 A JP2021549617 A JP 2021549617A JP 2021549617 A JP2021549617 A JP 2021549617A JP WO2020174283 A5 JPWO2020174283 A5 JP WO2020174283A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- alkyl
- group
- hydrogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 201000009273 Endometriosis Diseases 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 claims 2
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108010002519 Prolactin Receptors Proteins 0.000 claims 2
- 102100029000 Prolactin receptor Human genes 0.000 claims 2
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 claims 2
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- 102000005602 Aldo-Keto Reductases Human genes 0.000 claims 1
- 108010084469 Aldo-Keto Reductases Proteins 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000004483 Dyspareunia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 102000011367 Prostanoid EP4 receptors Human genes 0.000 claims 1
- 108050001693 Prostanoid EP4 receptors Proteins 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000013872 defecation Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810163P | 2019-02-25 | 2019-02-25 | |
| US62/810,163 | 2019-02-25 | ||
| PCT/IB2020/000160 WO2020174283A1 (en) | 2019-02-25 | 2020-02-24 | Treatment with p2x3 modulators |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022521955A JP2022521955A (ja) | 2022-04-13 |
| JP2022521955A5 JP2022521955A5 (https=) | 2023-02-24 |
| JPWO2020174283A5 true JPWO2020174283A5 (https=) | 2023-02-24 |
| JP7578602B2 JP7578602B2 (ja) | 2024-11-06 |
Family
ID=72239247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549617A Active JP7578602B2 (ja) | 2019-02-25 | 2020-02-24 | Ｐ２ｘ３修飾薬での治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12485125B2 (https=) |
| EP (1) | EP3930722A4 (https=) |
| JP (1) | JP7578602B2 (https=) |
| CN (1) | CN113727716A (https=) |
| AU (1) | AU2020228760A1 (https=) |
| CA (1) | CA3131312A1 (https=) |
| IL (1) | IL285772A (https=) |
| WO (1) | WO2020174283A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020228760A1 (en) | 2019-02-25 | 2021-09-23 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment with P2X3 modulators |
| JP2023513373A (ja) * | 2020-02-14 | 2023-03-30 | べルス・ヘルス・コフ・インコーポレーテッド | Ｐ２ｘ３修飾薬 |
| WO2021244634A1 (zh) * | 2020-06-05 | 2021-12-09 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| CN116635389A (zh) * | 2021-01-29 | 2023-08-22 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| CN115043836B (zh) * | 2021-08-20 | 2023-07-18 | 苏州璞正医药有限公司 | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 |
| GB202212749D0 (en) * | 2022-09-01 | 2022-10-19 | Gesynta Pharma Ab | New uses |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH503559A (de) | 1969-02-26 | 1971-02-28 | Arx Paul Von | Vorrichtung an Tafelschere zum Schneiden nach Markierungen, unter ständiger Beobachtung des Schnittes |
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| AU2002305236A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent |
| SE0102808D0 (sv) | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| MX2007003105A (es) | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. |
| MX2007013595A (es) | 2005-05-04 | 2008-01-24 | Renovis Inc | Compuestos heterociclicos fusionados y composiciones y usos de estos. |
| DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| CA2737038A1 (en) | 2008-09-18 | 2010-03-25 | Evotec Ag | Amide compounds, compositions and uses thereof |
| BR112012011518B8 (pt) | 2009-11-18 | 2023-01-10 | Astrazeneca Ab | Compostos, composição farmacêutica, kit e usos de um composto |
| WO2012158117A1 (en) | 2011-05-17 | 2012-11-22 | Astrazeneca Ab | Combination therapies for treating pain |
| JP5893135B2 (ja) | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途 |
| US9598409B2 (en) | 2013-01-31 | 2017-03-21 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| WO2015021998A1 (en) | 2013-08-15 | 2015-02-19 | Volvo Truck Corporation | Method and arrangement for balancing an energy storage system |
| RU2650118C2 (ru) | 2013-08-23 | 2018-04-09 | Афферент Фармасьютикалз Инк. | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться |
| HUE058009T2 (hu) | 2014-12-09 | 2022-06-28 | Bayer Ag | 1,3-Tiazol-2-il szubsztituált benzamid-származékok |
| KR20180054843A (ko) | 2015-09-29 | 2018-05-24 | 애퍼런트 파마슈티컬스 인크. | 기침 치료에 사용하기 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조정제 |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| MA43821A (fr) | 2016-03-14 | 2018-11-28 | Afferent Pharmaceuticals Inc | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| US11186872B2 (en) | 2016-03-17 | 2021-11-30 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through RNASET2 |
| CN109996546B (zh) | 2016-09-30 | 2023-06-27 | 阿沙纳生物科学公司 | P2x3和/或p2x2/3化合物及方法 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CN108904507A (zh) | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
| MX2021005424A (es) * | 2018-11-13 | 2021-06-15 | Bellus Health Cough Inc | Formas cristalinas de un compuesto de imidazopiridina sustituida y uso del mismo como modulador del receptor p2x3. |
| WO2020112890A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| WO2020135771A1 (zh) | 2018-12-29 | 2020-07-02 | 武汉朗来科技发展有限公司 | 杂环类化合物、中间体、其制备方法及应用 |
| AU2020228760A1 (en) | 2019-02-25 | 2021-09-23 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment with P2X3 modulators |
| JP2023513373A (ja) | 2020-02-14 | 2023-03-30 | べルス・ヘルス・コフ・インコーポレーテッド | Ｐ２ｘ３修飾薬 |
| EP4103572A4 (en) | 2020-02-14 | 2024-03-06 | Bellus Health Cough Inc. | MAKING A P2X3 ANTAGONIST |
-
2020
- 2020-02-24 AU AU2020228760A patent/AU2020228760A1/en not_active Abandoned
- 2020-02-24 WO PCT/IB2020/000160 patent/WO2020174283A1/en not_active Ceased
- 2020-02-24 EP EP20763699.4A patent/EP3930722A4/en active Pending
- 2020-02-24 CA CA3131312A patent/CA3131312A1/en active Pending
- 2020-02-24 CN CN202080031287.8A patent/CN113727716A/zh active Pending
- 2020-02-24 JP JP2021549617A patent/JP7578602B2/ja active Active
-
2021
- 2021-08-22 IL IL285772A patent/IL285772A/en unknown
- 2021-08-30 US US17/461,988 patent/US12485125B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2241285T3 (es) | Derivados bencimidazol como moduladores de ige. | |
| ES2705001T3 (es) | Tratamiento de neoplasias hematológicas con un anticuerpo anti-CXCR4 | |
| RU2018144427A (ru) | Способы лечения ar+ рака молочной железы | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| US20130052190A1 (en) | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions | |
| JP2012515787A5 (https=) | ||
| JP2021530513A5 (https=) | ||
| JP2006528231A (ja) | プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物 | |
| JP2009541209A5 (https=) | ||
| CN1325304A (zh) | 用于治疗偏头痛的5ht1受体激动剂和甲氧氯普胺 | |
| HRP20100366T1 (hr) | Antagonisti receptora progesterona | |
| RU2009131454A (ru) | Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств | |
| EP2455081A1 (en) | S1P1 receptor agonists for use in the treatment of crohn's disease | |
| JP2012515788A5 (https=) | ||
| JP2003519228A5 (https=) | ||
| JP2021530525A5 (https=) | ||
| US20020107244A1 (en) | Combination treatment for depression | |
| AU2017328999B2 (en) | Combination of FXR agonists | |
| JPWO2020174283A5 (https=) | ||
| KR20020090153A (ko) | 알콜중독 또는 알콜 의존을 위한 배합 치료 | |
| JP2009501745A5 (https=) | ||
| AU4373600A (en) | Combination therapy for the treatment of migraine | |
| WO2021194991A1 (en) | Use of losmapimod for treatment of covid-19 | |
| JP2000198734A (ja) | 胃運動性減弱および関連疾患の治療のための運動性増強薬 | |
| JP2010513489A5 (https=) |